Acquisitions strengthen activities in imaging and clinical assessment

The strategic acquisition of French imaging specialist Keosys, and B.Research, an eCOA platform based in Australia, has strengthened the offerings and footprint of Banook Group, a global provider of technology and services for clinical trial operators and currently a European leader in cardiac safety.

With close to 120 employees worldwide and a direct presence in Europe (France, Germany, UK, Italy), North America (USA, Canada) and Asia-Pacific (Australia), the Group (Nancy, France) has positioned itself as a key partner for world-renowned pharmaceutical laboratories, biotechnology companies and Contract Research Organisations (CROs).

“With the acquisition of Nabios in Germany in 2021 we secured our leading position in cardiac safety in Europe. We are now strengthening our central imaging activity with Keosys and expanding our offerings with eCOA through B.Research. These also enable us to reach a critical size. To continue responding to our client demands, we are focused on accelerating our international development, particularly in the United States and diversifying our offers. Our priority is to offer an excellent and comprehensive service while continuing our innovation efforts to support the health of tomorrow,” said Alexandre Durand-Salmon, CEO of Banook Group.

Based in Nantes since 2001, Keosys acts as a main partner for biotechs and pharmaceutical laboratories assessing the efficacy of drug-candidates. The company also has an office in New York (representing more than 30% of its activity) and all 40 employees, including the management team, will join this new growth project.

“This alliance with Banook was an obvious choice. We are two complementary players with international ambitions operating in the clinical trials market. Together, we can respond to a larger number of client requests and mutualize our efforts to develop our activities in North America. We are delighted to embark on a new stage in our development alongside the Banook team,” stated Arthur Painvin, CEO of Keosys.

The B.Research, eCOA (electronic Clinical Outcomes Assessments) platform based in Australia and acquired from Alira Health, brings technology to the Group that will enable the digitalisation of clinical data generated by patients. The collected data is usually qualitative information to assess the impact of the drug-candidate on the patient, beyond vital functions. With the majority of its staff in Sydney (Australia), the acquisition of B.Research will also enable Banook to develop a commercial team dedicated to the Asia-Pacific region.

“We are already receiving an abundance of inquiries for eCOA projects and are pleased to now better respond to our clients’ needs. The acquisition of B.Research is a highly strategic development for the Group and broadens our extensive offering yet further,” added Alexandre Durand-Salmon.

Since November 2023, Banook Group has been supported by the private equity fund Motion Equity Partners to accelerate its external growth strategy.

More information online